Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Graig Suvannavejh
MIZU
Graig Suvannavejh
Mizuho Securities
Wall Street Analyst
★☆☆☆☆
#2524
on 13Foresight · ranked by our own returns
36%
Success Rate
-8.2%
Average Return
16 of 44 calls profitable · -16.1% vs benchmark
📈 Across the calls we could measure, roughly 36% of Graig Suvannavejh's ratings turned a profit when each position was held for 1 year — averaging -8.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

250 Buy 45 Hold 0 Sell
Graig's Stock Coverage 58 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
NMRA
Neumora Therapeutics, Inc.
 Jun 18, 2026 BUY Strong Buy
+427.6% avg upside
11 analysts
$4.00
178.84% Upside
 ·
VSTM
Verastem
 Jun 17, 2026 BUY Strong Buy
+254.8% avg upside
23 analysts
$14.00
234.89% Upside
 ·
IMRX
Immuneering
 Jun 16, 2026 BUY Strong Buy
+305.9% avg upside
10 analysts
$12.00
181.77% Upside
 ·
IDYA
IDEAYA Biosciences
 Jun 16, 2026 BUY Strong Buy
+55.3% avg upside
29 analysts
$50.00
61.89% Upside
 +0.0%
INSM
Insmed
 Jun 15, 2026 BUY Strong Buy
+80.3% avg upside
36 analysts
$192.00
99.83% Upside
 +1.0%
CRVS
Corvus Pharmaceuticals
 Jun 12, 2026 BUY Strong Buy
+114.4% avg upside
14 analysts
$30.00
155.33% Upside
 +0.6%
HRMY
Harmony Biosciences Holdings
 Jun 11, 2026 BUY Strong Buy
+38.7% avg upside
13 analysts
$50.00
50.88% Upside
 ·
EYPT
EyePoint Pharmaceuticals
 Jun 05, 2026 BUY Strong Buy
+129.0% avg upside
17 analysts
$36.00
169.79% Upside
 +9.8%
LONA
LeonaBio
 Jun 05, 2026 BUY Buy
+12.0% avg upside
9 analysts
$16.00
89.87% Upside
 ·
AXSM
Axsome Therapeutics
 Jun 04, 2026 BUY Strong Buy
-10.5% avg upside
28 analysts
$310.00
25.00% Upside
 +8.8%
PVLA
Palvella Therapeutics
 Jun 04, 2026 BUY Strong Buy
+46.0% avg upside
27 analysts
$240.00
116.28% Upside
 -1.5%
TARS
Tarsus Pharmaceuticals
 May 27, 2026 BUY Strong Buy
+21.3% avg upside
16 analysts
$100.00
59.32% Upside
 ·
CRBP
Corbus Pharmaceuticals
 May 27, 2026 BUY Strong Buy
+346.7% avg upside
20 analysts
$44.00
447.34% Upside
 ·
BLTE
Belite Bio, Inc. ADR
 May 26, 2026 BUY Strong Buy
+24.3% avg upside
10 analysts
$215.00
48.86% Upside
 -2.7%
IMMX
Immix Biopharma
 May 26, 2026 BUY Strong Buy
+79.1% avg upside
7 analysts
$15.00
61.49% Upside
 ·
IMTX
Immatics
 May 14, 2026 BUY Strong Buy
+90.4% avg upside
15 analysts
$25.00
158.45% Upside
 -2.7%
ALEC
Alector
 May 12, 2026 HOLD Hold
+606.7% avg upside
14 analysts
$1.50
6.83% Downside
 +0.0%
AMLX
Amylyx Pharmaceuticals Inc
 May 11, 2026 BUY Strong Buy
+48.4% avg upside
13 analysts
$21.00
36.63% Upside
 +3.3%
IMCR
Immunocore Holdings
 May 08, 2026 HOLD Strong Buy
+125.2% avg upside
22 analysts
$34.00
18.60% Upside
 -5.2%
ERAS
Erasca
 Dec 09, 2025 BUY Strong Buy
+36.4% avg upside
14 analysts
$5.00
64.08% Downside
 +323.6%
KALA
KALA BIO
 Oct 02, 2025 HOLD Strong Buy
+7343.1% avg upside
9 analysts
$75.00
2243.71% Upside
 -96.6%
BTAI
Bioxcel Therapeutics
 Sep 16, 2025 HOLD Buy
+1935.1% avg upside
12 analysts
$4.00
234.71% Upside
 -59.5%
ADAPY
Adaptimmune Therapeutics
 Aug 26, 2025 HOLD Buy
+5717.9% avg upside
10 analysts
 — ·
GB:0QW0
arGEN X
 Jun 10, 2022 BUY Strong Buy
-22.6% avg upside
24 analysts
$400.00
48.02% Downside
 ·
IT:PHIL
Philogen SpA
 May 05, 2022 HOLD Hold
-24.7% avg upside
2 analysts
$16.50
27.45% Downside
 ·
GB:0MGB
Genmab A/S
 May 05, 2022 HOLD Buy
+34.6% avg upside
22 analysts
$2754.00
70.57% Upside
 ·
CH:IDIA
Idorsia Ltd
 May 05, 2022 HOLD Hold
-22.9% avg upside
8 analysts
$17.00
197.11% Upside
 ·
HALO
Halozyme
 Nov 15, 2021 BUY Strong Buy
-13.1% avg upside
20 analysts
$50.00
25.78% Downside
 +41.4%
AUTL
Autolus Therapeutics
 Nov 09, 2021 HOLD Strong Buy
+597.7% avg upside
16 analysts
$6.50
329.01% Upside
 -66.6%
FR:DBV
DBV Technologies
 Oct 28, 2021 BUY Hold
+85.8% avg upside
3 analysts
$6.00
113.71% Upside
 ·
NL:LKFT
Galapagos
 Oct 05, 2021 SELL Sell
+112.0% avg upside
16 analysts
$44.00
77.75% Upside
 ·
FR:VLA
Valneva
 Sep 21, 2021 BUY Strong Buy
+287.5% avg upside
3 analysts
$14.50
527.53% Upside
 ·
RYTM
Rhythm Pharmaceuticals
 Aug 04, 2021 SELL Strong Buy
+26.0% avg upside
19 analysts
$16.00
83.46% Downside
 -33.9%
CYTK
Cytokinetics
 Jul 20, 2021 HOLD Strong Buy
+9.9% avg upside
36 analysts
$26.00
66.60% Downside
 +33.1%
FR:IPH
Innate Pharma SA
 Jun 29, 2021 HOLD Strong Buy
+453.3% avg upside
5 analysts
$3.50
120.60% Upside
 ·
KOD
Kodiak Sciences
 May 14, 2021 HOLD Buy
+38.1% avg upside
11 analysts
$96.00
170.50% Upside
 -93.4%
ZLDPF
Zealand Pharma
 May 13, 2021 BUY Buy
+92.5% avg upside
11 analysts
$34.96
21.91% Downside
 ·
DSGN
Design Therapeutics
 Apr 20, 2021 HOLD Strong Buy
+47.9% avg upside
9 analysts
$28.00
133.78% Upside
 -30.9%
EWTX
Edgewise Therapeutics
 Apr 19, 2021 HOLD Strong Buy
+27.2% avg upside
14 analysts
$31.00
13.52% Downside
 -70.7%
IRON
Disc Medicine
 Mar 02, 2021 BUY Strong Buy
+21.2% avg upside
21 analysts
$20.00
71.59% Downside
 -91.3%
ARQT
Arcutis Biotherapeutics
 Feb 03, 2021 BUY Strong Buy
+50.8% avg upside
14 analysts
$55.00
115.38% Upside
 -57.6%
DBVT
DBV Technologies SA - American
 Jan 15, 2021 BUY Strong Buy
+49.4% avg upside
15 analysts
$7.00
56.34% Downside
 -71.0%
LKFT
Lakefront Biotherapeutics
 Dec 21, 2020 SELL Hold
+272.1% avg upside
24 analysts
$90.00
218.66% Upside
 ·
IPHA
Innate Pharma
 Nov 23, 2020 HOLD Strong Buy
+267.3% avg upside
10 analysts
$4.75
165.44% Upside
 -3.8%
JAZZ
Jazz Pharmaceuticals
 Nov 11, 2020 SELL Strong Buy
-1.8% avg upside
35 analysts
$145.00
34.59% Downside
 +8.2%
PRLD
Prelude Therapeutics
 Oct 20, 2020 HOLD Buy
+153.1% avg upside
7 analysts
$37.00
772.70% Upside
 -38.1%
BCYC
Bicycle Therapeutics
 May 11, 2020 BUY Strong Buy
+502.2% avg upside
20 analysts
$19.00
376.25% Upside
 +105.0%
KRYS
Krystal Biotech
 Sep 24, 2019 HOLD Strong Buy
-27.6% avg upside
19 analysts
$60.00
82.60% Downside
 +0.4%
ARGX
Argenx Se
 Dec 17, 2018 BUY Strong Buy
-16.4% avg upside
46 analysts
$154.00
82.33% Downside
 +58.3%
TGTX
TG Therapeutics
 Sep 23, 2014 BUY Strong Buy
-32.7% avg upside
19 analysts
$16.00
69.31% Downside
 ·
MNKD
MannKind
 Jul 01, 2014 HOLD Buy
+79.6% avg upside
22 analysts
$11.00
181.41% Upside
 -45.9%
ACUR
Acura Pharmaceuticals
 May 28, 2014 HOLD Buy
+749900.0% avg upside
2 analysts
$1.00
249899.96% Upside
 ·
XOMA
XOMA Royalty Corporation
 Apr 29, 2014 BUY Buy
-46.2% avg upside
11 analysts
$7.00
83.19% Downside
 -29.8%
ATHE
Alterity Therapeutics
 Apr 01, 2014 HOLD Strong Buy
+62.5% avg upside
5 analysts
$3.00
38.19% Downside
 -51.3%
LGND
Ligand Pharma
 Feb 13, 2014 BUY Strong Buy
-18.2% avg upside
15 analysts
$96.00
64.34% Downside
 -29.4%
ORMP
Oramed Pharm
 Feb 03, 2014 BUY Strong Buy
+403.4% avg upside
7 analysts
$27.00
597.68% Upside
 -71.5%
FBIO
Fortress Biotech
 Oct 15, 2013 HOLD Strong Buy
+158.8% avg upside
12 analysts
$2.00
34.04% Downside
 +7.0%
ALKS
Alkermes
 Mar 22, 2012 BUY Strong Buy
-16.4% avg upside
34 analysts
$24.00
45.71% Downside
 +37.0%
🔒 53 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Graig Suvannavejh — Frequently Asked Questions
How accurate are Graig Suvannavejh's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Graig's ratings were profitable over a one-year hold, with an average return of -8.3% per rating, or -16.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Graig ranked on 13Foresight?
Graig Suvannavejh is currently ranked #2524 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Graig cover?
Graig most recently has ratings on NMRA, VSTM, IMRX, IDYA, INSM, CRVS, HRMY, EYPT, LONA, AXSM, PVLA, TARS and 46 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.